Cassava Sciences, Inc. (SAVA)
After hours:
| Previous close | 31.52 |
| Open | 30.96 |
| Bid | 30.20 x 1100 |
| Ask | 30.88 x 800 |
| Day's range | 30.46 - 32.35 |
| 52-week range | 13.84 - 62.49 |
| Volume | |
| Avg. volume | 1,580,355 |
| Market cap | 1.29B |
| Beta (5Y monthly) | -0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | N/A |
- Motley Fool
3 Big Reasons to Sell Cassava Sciences Stock Right Now
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
- Zacks
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
- Simply Wall St.
Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst individual investors who own 69% of the shares, institutions hold 25%
If you want to know who really controls Cassava Sciences, Inc. (NASDAQ:SAVA), then you'll have to look at the makeup of its share registry...
